QualityDipStocks / Health Care · Pharmaceuticals
Sanofi ADS SNY
Outside our quality screen, so we don’t track its dips. It’s 15% below its 52-week high.
Outside our quality screen, trading well below our fair value estimate.
- Fair value est.
- $61.99+40%
- Market Value
- —
- Off 52-wk high
- −15%
- Risk vs market
- Lowbeta 0.23
5 bullish · 4 bearish See why
Key levels
Every level vs today’s $44.34
- 52-wk lowlowest close, 1 year$39.12−11.8%
- PriceFri Oct 30 close$44.34you are here
- 52-wk highhighest close, 1 year$52.34+18.0%
- Fair value est.base case$61.99+39.8%
Fair value estimate
How the range is computed
Ten-year free-cash-flow DCF. Same 10-year free-cash-flow model as the base: discount rate 9.5% ±1 point and growth 6.0% ±2 points. Bear = 10.5% and 4.0%; bull = 8.5% and 8.0% (both fade to 3%). A model estimate from public filings, not a forecast of where the price will go.
Price is below even the bear case.
What the price implies To be worth today’s price, SNY’s free cash flow would need to stay flat for five years; our estimate uses 6%.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much SNY moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Has moved mostly independently of the market, but its own price swings are 1.8× the S&P 500’s (it moves on its own news).
- Beta vs S&P 500
- 0.23
- Volatility
- 24% vs 13% SPY
- Correlation SPY
- 0.13
- Correlation QQQ
- −0.06
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 5 of 5
ValuationOur DCF fair value estimate is $61.99, 40% above the price.
ValuationP/E of 12.4× vs a 29.2× median for the 86 Health Care companies we cover.
ValuationFree-cash-flow yield of 7.4% (price / FCF 13.4×): $8.1B of free cash in the last 12 months.
Balance sheetNet cash of $3.7B: cash and short-term investments exceed debt (Dec 31, 2025).
Cash returnsFree cash flow grew 23% over the last 12 months vs the 12 months before.
Top bearish points 4 of 5
Balance sheetDebt rose 112% to $4.9B from FY2023 to FY2025.
ProfitabilityReturn on invested capital of 7.4%, below the 11% median for the 61 Health Care companies we cover.
ProfitabilityReturn on equity of 10%, below the 13% median for the 91 Health Care companies we cover.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
Who’s talking about it
Notable investors, executives, analysts and public figures on Sanofi ADS in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Pharmaceuticals
All fundamentals
P/E 12.4 · FCF yield 7.4% · ROE 10%
Valuation
- P/E
- 12.4×Health Care median 29.2×
- Price / FCF
- 13.4×
- FCF yield
- 7.4%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- n/anot reported in its SEC filings
- Price / book
- 1.36×
- Market cap
- $109Bprice × diluted shares
- Enterprise value
- $105B
Growth
- Revenue, 12 months
- n/anot reported in its SEC filings
- Sales growth, 12 months
- n/ano year-ago 12-month revenue
- Sales growth, 3 yrs
- n/anot reported in its SEC filings
- Diluted EPS, 12 months
- $6.37
- EPS growth, last FY
- +43.8%
- Net income, 12 months
- $8.8B
- Net income growth
- +41%12 months vs before
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- n/anot reported in its SEC filings
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- 10%
- Return on invested capital
- 7%
Balance sheet
- Cash & short-term inv.
- $8.6B
- Total debt
- $4.9B
- Net cash
- $3.7B
- Debt / equity
- 0.06×
- Interest coverage
- 11.3×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $8.1B
- FCF growth, 12 months
- +23%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- $5.6B5.2% of market cap
- Share count, 1 year
- n/ano quarterly diluted share count
- Stock-based comp
- n/anot reported in its SEC filings
Trailing 12 months to Dec 31, 2025; balance sheet at Dec 31, 2025. From Sanofi ADS’s SEC filings, reported in EUR and converted to US dollars. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
DCF $61.99 · FCF value $73.76
Assumes 6.0% growth for 5 years (default; under two years of revenue in SEC data), fading to 3%; 9.5% discount rate, 3% terminal growth. FCF base $3.30 a share (fiscal year to Dec 31, 2025, converted from EUR at 1.123, 0.5 shares per ADR), from the 20-F filed Feb 17, 2026. Net debt $17.3B, not deducted.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 68 · 5 days +6.6%
The business
FCF $7.0B · Sales +15%
- Free cash flow, 12 months$7.0B
- Free-cash-flow yield6.7%
- Free-cash-flow margin14%
- Gross margin73%
- Operating margin21%
- Return on invested capital9%
- Return on equity6%
- Sales growth (latest quarter vs year-ago quarter)+15%
- Net debt / EBITDA2.1×
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
SNY is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.